• NanoBio Corp., of Ann Arbor, Mich., closed an $11 million Series C financing, including full participation from its existing investor syndicate. Proceeds will be used to advance the firm's development programs for herpes labialis, cystic fibrosis and nanoemulsion-based vaccines for respiratory syncytial virus and genital herpes.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter